Trans-Mucosal Drug Delivery Technology (TMDD)
Product Description
Holy Stone Healthcare Co., Ltd.
-
TW
-
2024On CPHI since
-
100 - 249Employees
Company types
Holy Stone Healthcare Co., Ltd.
-
TW
-
2024On CPHI since
-
100 - 249Employees
Company types
More Products from Holy Stone Healthcare Co., Ltd. (3)
-
Product HDD Technology: Hyaluronan Drug Delivery
Holy Stone Healthcare focuses on biopolymers to develop novel drug delivery technologies. Our "Biopolymer drug delivery platform" exploits the biological safety, compatibility, degradability and other characteristics of natural polysaccharides. We have made full use of non-toxic, non-immunogenic, non-infl... -
Product Hyaluronic Acid Conjugated Drugs, HACD
We have developed a “targeting” treatment based on the fact that hyaluronic acid specifically combines with cell surface receptors, glycoprotein CD44 (cluster of differentiation 44) and RHAMM (receptor for hyaluronan mediated motility), which are highly expressed in certain cancer cells. We then select ant... -
Product Multi-Layer Coating Pellet Technology (MLCP)
Multi-layer coating pellet technology (MLCP) is a manufacturing technology developed under the Hyaluronan Drug Delivery technology platform. Using an advanced fluid bed technology, we coat pellets with a patented formulation of drug and HA in multiple layers to produce an oral dosage form targeted to relea...
Holy Stone Healthcare Co., Ltd. resources (1)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance